The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like peptide-1 (GLP-1). Since GLP-1-based therapy is a promising novel treatment of type 2 diabetes, the strategy to ...

A study published in the American Journal of Ophthalmology suggests that the use of SGLT2 inhibitors in diabetes is linked to ...

A total of 20,146 patients with nephrolithiasis and type 2 diabetes, including those with gout at baseline, initiated an SGLT ...

The following is a summary of “Sodium-glucose cotransporter 2 inhibitors and glaucoma in patients with type 2 diabetes,” ...

Researchers from the US have shown that combination therapy with sitagliptin and metformin results in a substantial and additive glycemic improvement in patients with type 2 diabetes. Sitagliptin ...

Grapefruit can interact with many medications, potentially affecting the way they work or increasing side effects. Some of ...

Human antibodies take center stage, as they pile up in the list of approved biologics in 2009. Cormac Sheridan reports. Last year was a vintage year for the bio-pharmaceutical industry in two ...

Semaglutide, the active ingredient in the diabetes and weight loss drugs Ozempic and Wegovy, could lower the risk for ...

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on INSM stock, giving a Buy rating on November 5. Graig ...

DelveInsight’s 'Non-Cystic Fibrosis Bronchiectasis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline non-cystic fibrosis bronchiectasis therapies in various stages of ...

They compared patients prescribed semaglutide—a glucagon-like peptide-1 (GLP-1) receptor agonist—to those prescribed one of ...

β-cell–Centric Construct: A Potential Model for the Classification of DM Given the above discussion, the issue is not "what is LADA" or any clinical presentation of DM under the current system.